alan venook, md, discusses vemurafenib and the nccn guidelines for mcrc patients
Published 6 years ago • 31 plays • Length 1:30
Download video MP4
Download video MP3
Similar videos
-
1:13
steven j. cohen, md, discusses vemurafenib and the nccn guidelines for mcrc patients
-
1:39
alan venook, md, discusses next generation sequencing and mcrc treatment
-
1:41
alan p. venook, md, explains how the 80405 study and its impact on treatment guidelines
-
1:05
alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients
-
1:42
dr. alan p. venook on determining frontline treatment for mcrc
-
1:47
alan venook, md discusses development of immunotherapies for non msi-high crc patients
-
0:25
alan venook, md on integrating regorafenib and trifluridine into the 2nd line treatment of mcrc
-
1:59
dr. venook on evolving treatment strategies in crc
-
34:17
colorectal cancer breakout: biomarkers for effective treatment
-
11:06
colorectal cancer: an overview
-
26:20
colorectal cancer: the link between the immune microenvironment and outcomes
-
1:13
alan venook, md, on the impact of dose escalation of regorafenib in mcrc patients
-
2:12
alan venook, md, considers how i-o is evolving towards the first line treatment of colorectal cancer
-
1:54
alan p. venook, md, on integrating immunotherapy into existing treatment regimens for hcc patients
-
1:38
alan venook, md explains the outcome of phase 3 calgb/swog 80405 study
-
2:03
alan venook, md, explains the biological difference between left-sided and right-sided crc tumors
-
1:44
alan venook, md, considers how immunotherapy is being integrated into crc treatment algorithms
-
0:48
dr. venook discusses the future of colorectal cancer treatment
-
1:54
alan venook, md, explains how tumor sidedness affects therapeutic choice
-
1:01
alan venook, md, balancing economics with the efficacy outcomes seen in 80405
-
10:06
understanding tumor sidedness in colorectal cancer
-
0:49
biomarker-driven approaches for anal cancer
Clip.africa.com - Privacy-policy